Following a 2-month closure, CHAIN reopened its laboratories in Nottingham on the 1st June. This comes after a risk assessment and change to working practices to maintain safe working for staff in the labs and office. MediCity has also implemented new measures in the building to support safe working practices which have also contributed to […]
An Oxford based nutritional company, TdeltaS Ltd (TΔS®), has developed and commercialised a proprietary ketone ester, which can be used as a food to improve human physical performance and cognitive function in health and disease. The Company’s product, ΔG®, is a ketone monoester that is marketed by HVMN Inc. in the USA for use in their sports […]
CHAIN is pleased to announce a new 18-month research collaboration with Associate Professor John Heap and his research group at the University of Nottingham. Dr Heap is Associate Professor of Synthetic Biology in the School of Life Sciences at the University of Nottingham, where he is also part of the newly-formed Biodiscovery Institute […]
Our Clostridium Assisted Drug Development (CADD™) platform provides superior gut delivery to support a pipeline of drug candidates addressing multiple therapeutic areas associated with the gut microbiome.
We target inflammatory bowel disease with a focus on Ulcerative Colitis. Our lead drug candidate is a live biotherapeutic engineered to produce anti-inflammatory metabolites; β-hydroxybutyrate and butyrate.